Comparative Pharmacology
Head-to-head clinical analysis: DIMETHYL SULFOXIDE versus NOURESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIMETHYL SULFOXIDE versus NOURESS.
DIMETHYL SULFOXIDE vs NOURESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dimethyl sulfoxide (DMSO) is a polar aprotic solvent that penetrates biological membranes, scavenges hydroxyl radicals, and stabilizes lysosomal membranes. It has anti-inflammatory, analgesic, and cryoprotective properties. It enhances cutaneous absorption of other drugs and induces histamine release from mast cells, causing vasodilation and urticaria.
Nouress is a combination product containing amino acids, electrolytes, and vitamins. The amino acids serve as substrates for protein synthesis, while electrolytes and vitamins support cellular metabolism and physiological functions. The exact mechanism of action is supportive nutrition.
50% solution topically applied every 6 hours; intravenous: 0.5-1 g/kg as a 10-20% solution over 30-60 minutes every 6 hours for 3-5 doses
Intravenous infusion: 100 mcg/min over 20 minutes, then 0.5-2 mcg/min continuous infusion.
None Documented
None Documented
Clinical Note
moderateDimethyl sulfoxide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Dimethyl sulfoxide."
Clinical Note
moderateDimethyl sulfoxide + Atorvastatin
"The risk or severity of adverse effects can be increased when Dimethyl sulfoxide is combined with Atorvastatin."
Clinical Note
moderateDimethyl sulfoxide + Dexrazoxane
"The therapeutic efficacy of Dexrazoxane can be decreased when used in combination with Dimethyl sulfoxide."
Clinical Note
moderateTerminal half-life: 11-14 hours for DMSO; DMSO2 half-life 60-70 hours, accumulates with repeated dosing. Clinical context: renal impairment prolongs half-life.
Terminal elimination half-life is 4-6 hours in patients with normal renal function. Clinically, this supports twice-daily dosing; half-life is prolonged in renal impairment.
Renal: 30-50% unchanged; hepatic metabolism to dimethyl sulfone (DMSO2) and dimethyl sulfide (DMS); DMSO2 excreted renally, DMS exhaled; fecal elimination <5%.
Primarily renal elimination as unchanged drug (60-70%), with biliary/fecal excretion accounting for 20-30%. The remainder is metabolized hepatically.
Category C
Category C
Topical Analgesic
Topical Analgesic
Metoprolol + Dimethyl sulfoxide
"The serum concentration of Dimethyl sulfoxide can be increased when it is combined with Metoprolol."